Reslizumab

Pharmacodynamic Biomarkers to Support Biosimilar Development: Interleukin-5 Antagonists

Efficacy of Reslizumab Dose Escalation in Patients With Severe Asthma

A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma

Similarities and Differences of Biological Therapies for Severe Asthma.

Study of Chronic Rhinosinusitis Symptoms in Asthma Patients Undergoing Treatment With Reslizumab

Reslizumab in Patients With Severe Asthma Who Failed to Respond to Omalizumab

Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

Effect of Reslizumab in Chronic Rhinosinusitis

Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

Efficacy and Safety Study of Reslizumab to Treat Poorly Controlled Asthma

Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma

Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma